## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
MB Number:	3235-0287					
stimated average burden						
ours per response	0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Typ	e Responses	)																
1. Name and Address of Reporting Person * Ahn Chang Ho					2. Issuer Name and Ticker or Trading Symbol REXAHN PHARMACEUTICALS, INC. [RNN]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last) (First) (Middle) C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455					3. Date of Earliest Transaction (Month/Day/Year) 01/20/2017								X Director 10% Owner Officer (give title below) Other (specify below)					
(Street)				4.	4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line)X_Form filed by One Reporting Person Form filed by More than One Reporting Person					
ROCKVILLE, MD 20850 (City) (State) (Zip)					Table I - Non-Derivative Securities Acqui								ired, Disposed of, or Beneficially Owned					
1.Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Year			ar) a	2A. Deemed Execution D arr) (Month/Day		date, if Coo (Ins	3. Trans Code (Instr. 8		4. S (A) (Ins	Securities Acquired or Disposed of Str. 3, 4 and 5)  (A) or nount (D)	uired 5. A	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)			Ownership of Sorm: Be Direct (D) Or Indirect (Indirect (	eneficial wnership		
Reminder: R	deport on a se	eparate line for each	class of securiti	es be	eneficial	ly o	wned direc	tly o	Pers	ons aine	who responed in this fore	m are not	required	to respond	d unless the		74 (9-02)	
			Table I								ed of, or Bene vertible securi		vned					
1. Title of Derivative Security (Instr. 3)  2.			3A. Deemed Execution Date, ar) (Month/Day/Ye		4. Transaction Code		5. Number of		6. Date Exercisable and Expiration Date (Month/Day/Year) S		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form of Derivative Security: Direct (D) or Indirect s) (I)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)		
Stock Option (right to buy)	\$ 0.184	01/20/2017			A		330,000		<u>(1</u>	Ĵ	01/20/2027	Commo Stock	<sup>1</sup> 330,000	\$ 0	330,000	D		
Restricted Stock Units	<u>(2)</u>	01/20/2017			A		70,000		<u>(3</u>	<u>)</u>	<u>(3)</u>	Commo Stock	70,000	\$ 0	70,000	D		
Report	ting O	wners																
Reporting Owner Name / Address  Direct				Relationships														
			ctor	or 10% Owner Officer Other														

## **Signatures**

ROCKVILLE, MD 20850

Ahn Chang Ho

/s/ Tae Heum Jeong, as attorney-in-fact for Chang Ho Ahn	01/24/2017
Signature of Reporting Person	Date

### **Explanation of Responses:**

C/O REXAHN PHARMACEUTICALS, INC.

15245 SHADY GROVE ROAD, SUITE 455

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

X

- (1) One quarter of the option vests and becomes exercisable on January 20, 2018, and, thereafter, 1/36th of the remaining option vests in equal installments on the first business day of each month until fully vested.
- (2) Each restricted stock unit represents a contingent right to receive one share of common stock.
- (3) The restricted stock units vest in four equal annual installments on the last business day in February, beginning February 28, 2018.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.